Emyria Limited (ASX:EMD)

Market Cap	46.78M +174.5%
Revenue (ttm)	1.39M -36.7%
Net Income	-3.14M
EPS	-0.01
Shares Out	806.52M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,995,156
Average Volume	1,661,026
Open	0.0530
Previous Close	0.0550
Day's Range	0.0530 - 0.0580
52-Week Range	0.0210 - 0.0780
Beta	0.06
RSI	46.60
Earnings Date	Feb 2, 2026

About Emyria

Emyria Limited engages in delivering and developing of treatments for mental health and select neurological conditions in Australia. The company operates through Clinical Services, Clinical Services, and corporate segments. It provides therapy programs for post-traumatic stress disorder (PTSD) and treatment-resistant depression. The company also develops ultra-pure CBD capsules (EMD-RX7, and EMD-RX9) and proprietary MDMA analogues, as well as provides psychological trauma care facility under the Pax Centre name. It has a collaboration partnersh...

• Industry: Health Information Services
• Sector: Healthcare
• Founded: 2018
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: EMD

Financial Performance

In fiscal year 2025, Emyria's revenue was 1.39 million, a decrease of -36.68% compared to the previous year's 2.20 million. Losses were -3.14 million, -72.57% less than in 2024.